Evidence map›Paper›PMID 30167847›Full record

ArticleCancer chemotherapy and pharmacology2018

Phase Ib study of irinotecan and ramucirumab for advanced gastric cancer previously treated with fluoropyrimidine with/without platinum and taxane.

Hironaga Satake, Tamotsu Sagawa, Koshi Fujikawa, Yukimasa Hatachi, Hisateru Yasui, Masahito Kotaka, Takeshi Kato, Akihito Tsuji

Open access · hybridAbstract readClinical Trial, Phase I
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer chemotherapy and pharmacology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
1.1field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it, 13 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. A multicenter phase II trial of ramucirumab plus irinotecan for early recurrence of gastric cancer during or after adjuvant chemotherapy with docetaxel plus S-1 therapy: the RAMIEL trial (OGSG1901).Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association · 2026
    Article
  5. Review
  6. Article
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 5 institutions in 1 country.

Hironaga SatakeCancer Treatment Center, Kansai Medical University Hospital, Hirakata, Osaka, Japan. takeh1977@gmail.com.ORCID 0000-0001-7629-6803
Tamotsu SagawaDivision of Medical Oncology, National Hospital Organization, Hokkaido Cancer Center, Sapporo, Hokkaido, Japan.
Koshi FujikawaDivision of Medical Oncology, National Hospital Organization, Hokkaido Cancer Center, Sapporo, Hokkaido, Japan.
Yukimasa HatachiDepartment of Medical Oncology, Kobe City Medical Center General Hospital, Kobe, Hyogo, Japan.
Hisateru YasuiDepartment of Medical Oncology, Kobe City Medical Center General Hospital, Kobe, Hyogo, Japan.
Masahito KotakaGastrointestinal Cancer Center, Sano Hospital, Kobe, Hyogo, Japan.
Takeshi KatoDepartment of Surgery, National Hospital Organization, Osaka National Hospital, Osaka, Osaka, Japan.
Akihito TsujiDepartment of Clinical Oncology, Kagawa University Hospital, Miki, Kagawa, Japan.
Kobe City Medical Center General Hospital · JPNational Hospital Organization Hokkaido Medical Center · JPKagawa University Hospital · JPKansai Medical University · JPOsaka National Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeOptimal salvage chemotherapy for patients with treated advanced/metastatic gastric cancer (AGC) is unknown. Irinotecan is commonly used in Japan. Ramucirumab, a human IgG-1 monoclonal antibody targeting the extracellular domain of VEGF receptor 2, is the first molecularly targeted agent proven to be effective in second-line therapy for AGC in combination with chemotherapy. We sought to determine the maximum tolerated dose (MTD) and recommended dose (RD) of ramucirumab plus irinotecan for AGC previously treated with fluoropyrimidine with/without platinum and taxane.

methodsPatients received systemic chemotherapy with ramucirumab (8 mg/kg) and irinotecan on day 1, repeated every 2 weeks. A decrease in irinotecan dose was planned from start level 1 (irinotecan 150 mg/m

resultsSix patients were enrolled from August 2015 to September 2017. No dose-limiting toxicity (DLT) was observed, and the maximum tolerated dose (MTD) was not reached at level 1. Irinotecan 150 mg/m

conclusionsSalvage chemotherapy with irinotecan plus ramucirumab was well-tolerated by patients previously treated for AGC. RD was defined as irinotecan 150 mg/m

Indexed as

AgedAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAntineoplastic Combined Chemotherapy ProtocolsBridged-Ring CompoundsDrug Administration ScheduleFemaleHumansIrinotecanKaplan-Meier EstimateMaleMaximum Tolerated DosePlatinumRamucirumabSalvage TherapyStomach NeoplasmsAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedBridged-Ring CompoundsIrinotecanPlatinumRamucirumabtaxaneTaxoidsAntagonists and inhibitors: topoisomerase I inhibitorsSalvage therapy/MTStomach neoplasms/DTVascular endothelial growth factor receptor/AI

Identifiers

PMID30167847
PMCPMC6182742
OpenAlexW2889140009

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.